Ether lipids enhance the cytotoxic effect of teniposide and paclitaxel in liposomes against leukaemic cells in culture

Anti-Cancer Drug Design

Volumn 12, Issue 6, 1997, Pages 503-513

  Lundberg, Bo B ^a  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Cancer drug; Drug combination; Ether lipid; Liposome; Synergism

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; EDELFOSINE; ETHER LIPID; LIPOSOME; OCTADECYLPHOSPHOCHOLINE; PACLITAXEL; PHOSPHOLIPID; TENIPOSIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; HEMOLYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; LIPID BILAYER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ANTAGONISM; DRUG SYNERGISM; HEMOLYSIS; HL-60 CELLS; HUMANS; JURKAT CELLS; LIPOSOMES; PACLITAXEL; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE; TENIPOSIDE;

EID: 0030804586     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. AHMAD, I., LONGENECKER, M., SAMUEL, J. & ALLEN, TM. (1993). Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Research, 53, 1484.
2. ALLEN, T.M., HANSEN, C., MARTUN, F., REDEMAN, C. & YAU-YOUNG, A. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica Biophysica Acta, 1066, 29.
3. ANDREESEN, R., MODOLELL, M, WELTZIEN, H.U, EIBL, H., COMMON, H.H , LOHR, G.W & MUNDER, PG. (1978). Selective destruction of human leukemic cells by alkyl-phospholipids. Cancer Research, 38, 3894.
4. ANDREESEN, R., MODOLELL, M., OEPKE, G.H.F., COMMON, H., LOHR, G.W. & MUNDER, P.G. (1982). Studies On various parameters influencing leukemic cell destruction by alkyl-lysophospholipids. Anticancer Research, 2, 95.
5. BERDEL, W.E. (1991). Membrane-interactive lipids as experimental anticancer drugs. British Journal of Cancer, 64, 208.
6. BJÖRKHOLM, M. (1990). Etoposide and teniposide in the treatment of acute leukemia. Medical Oncology and Tumor Pharmacotherapy, 7, 3.
7. BORK, E., HANSEN, M., DOMBERNOWSKY, P., HANSEN, S.W, PEDERSEN, A.G. & HANSEN, H.H. (1986). Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. Journal of Clinical Oncology, 4, 524.
8. BUTTKE, T.M., MCCUBREY, J A. & OWEN, T C. (1993). Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. Journal of Immunological Methods, 157, 233.
9. CABANES, A., BRIGGS, K.E., GOKHALE, P.C. & RAHMAN, A. (1996) Pharmacokinetics, tissue distribution and in vivo toxicity of liposome-encapsulated taxol. Proceedings of the American Association for Cancer Research, 37, 370.
10. CHOU T.-C. & TALALAY, p. (1986). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27.
11. COUNSELL; R.E , SCHWENDNER, S W., MEYER, K.L , HARADAHIRA, T. & GROSS, M.D (1990) Tumor visualization with a radioiodinated phospholipid ether. Journal of Nuclear Medicine, 31, 332.
12. DIETZFELBINGER. H.F., KUHN, D., ZAFFERANI, M., HANAUSKE, A.R., RASTETTER, J.W. & BERDEL, W.E. (1993). Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Cancer Research, 53, 3747.
13. DOMBERNOWSKY, P. & HANSEN, H.H. (1989). The epipodophyllotoxin derivatives VM 26 and VP 16: experimental and clinical aspects. European Journal of Haematology, 42, 49.
14. EIBL, H. & UNGER, C. (1990) Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treatment Reviews, 17, 233.
15. FICHTNER, I., ZEISIG, R., NAUNDORF, H., JUNGMANN, S., ARNDT, D., ASONGWE, G., DOUBLE, J.A. & BIBBY, M.C. (1994) Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes. Breast Cancer Research and Treatment, 32, 269.
16. FREI, E. (1991). III. Clinical studies of combination chemotherapy for cancer. In Synergism and Antagonism in Chemotherapy. Chou, T-C. and Rideout, D.C. (eds), p. 103. Academic Press Inc.: San Diego, CA.
17. GRIEDER, A., MAURER, R & STÄHELIN, H. (1974). Effect of an epipodophyllotoxin derivative (VP-16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro. Cancer Research, 34, 1788.
18. HOLMES, F.A., WALTERS, R.S., THERIAULT, R.L., FORMAN, A.D., NEWTON, L.K., RABER, M N., BUZDAR, A.U., FRYE, D.K. & HORTOBAGYI, G.N. (1991). Phase II trial on taxol, an active drug in the treatment of metastatic breast cancer. Journal of the National Cancer Institute, 83, 1797.
19. JORDAN, M A., TOSO, R.J., THROWER, D. & WILSON, L. (1993). Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proceedings of the National Academy of Sciences, USA, 90, 9552.
20. LIEBMANN, J.E., COOK, J.A , LIPSCHOLTZ, C., TEAGUE, T., FISHER & J., MITCHELL. J.B. (1993). Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. British Journal of Cancer, 68, 1104.
21. LUNDBERG, B. (1994). The solubilization of lipophilic derivatives of podophyllotoxins in sub-micron sized lipid emulsions and their cytotoxic activity against cancer cells in culture. International Journal of Pharmacy, 109, 73.
22. LUNDBERG, B. (1997). A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). Journal of Pharmacy and Pharmacology, 49, 16.
23. LUNDBERG, B., HONG, K. & PAPAHADJOPOULOS, D (1993). Conjugation of apolipoprotein B with liposomes and targeting to cells in culture Biochimica et Biphysica Acta, 1149, 305.
24. MAYHEW, E.G, LASIC, D., BABBAR, S & MARTIN, F.J. (1992). Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycolderivatized phospholipid. International Journal of Cancer, 51, 302.
25. NOSEDA, A , BERENS, M., WHITE, J G. & MODEST, E J (1988). In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells. Cancer Research, 48, 1788.
26. OKAMOTO, S., OLSON, A.C., VOGLER, W.R. & WINTON, E.F. (1987). Purging leukemic cells from simulated human remission marrow with alkyllysophospholipid. Blood, 69, 1381.
27. POSTMA, T.J., VERMORKEN, J.B, LIEFTING, A.J., PINEDO, H.M. & HEIMANS, J.J. (1995). Paclitaxel-hlduced neuropathy. Annals of Oncology, 6, 489.
28. PRINCIPE, P, SIDOTI, C. & BRAQUET, P (1992a). Tumor cell kinetics following ether phospholipid treatment. Cancer Research, 52, 2509.
29. PRINCIPE, P., COULOMB, C., BROQUET, C & BRAQUET, P. (1992b). Evaluation of combinations of antineoplastic ether phospholipids and chemotherapeutic drugs. Anti-Cancer Drugs, 3, 577.
30. RAFAELOFF, R., HUSAIN, S.R & RAHMAN, A. (1992) Liposomes-encapsulated taxol (LET) is an effective modality to circumvent multidrug resistance (MDR) phenotype. Proceedings of the American Association for Cancer Research, 33, 2883.
31. RIONDEL, J., JACROT, M., FESSI, H , PUISIEUX, F. & POTIER, P. (1992) Effects of free and liposome- encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo, 6, 23.
32. ROSE, W.C. (1992) Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs, 3, 311.
33. ROWINSKY, E.K. & DONEHOWER, R.C. (1995) Paclitaxel (Taxol). New England Journal of Medicine, 332, 1004.
34. RUNOWICZ, C.D., WIERNIK, P.H., EINZIG, A I., GOLDBERG, G.L. & HORWITZ, S B (1993) Taxol in ovarian cancer. Cancer, 71, 1591.
35. SCULIER, J.P., COUNE, A., RASSINNE, C.B., LADURAN, C., ATASSI, G., RUYSSCHERT, J.M. & FRUHLING, J. (1986). Intravenous infusion of high doses of liposomes containing NSC251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetics data. Journal of Clinical Oncology, 4, 789.
36. SHARMA, A. & STRAUBINGER, R.M. (1994). Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharmaceutical Research, 11, 889.
37. SHARMA, A., MAYHEW, E. & STRAUBINGER, R.M (1993). Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Research, 53, 5877.
38. UNGER, C., SINDERMANN, H., PEUKERT, M., HILGARD, P., ENGEL, J. & EIBL, H (1992). Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Progress in Experimental Tumor Research, 34, 153.
39. VERWEIJ, J., GANDIA, D., PLANTING, A.S.T, STOTER, G & ARMAND, J.P. (1993) Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. European Journal of Cancer, 29, 778.
40. WEBB, J.L. (1963) Enzyme and Metabolic Inhibitors Vol. 1, p. 507. Academic Press: New York.
41. WEISS, R.B., DONEHOWER, R.C., WIERNIK, P.H., OHNUMA, T., GRALLA, R.J, TRUMP, D.L., BAKER, J.R., VAN ECHO, D.A., VON HOFF, D.D. & LEYLAND-JONES, B. (1990). Hypersensitivity reaction from taxol. Journal of Clinical Oncology, 8, 1263.
42. ZEISIG, R., FICHTNER, I., ARNDT, D. & JUNGMANN, S. (1991). Antitumor effects of alkyl phosphocholines in different murine tumor models: use of liposomal preparations. Anti-Cancer Drugs, 2, 411.
43. ZEISIG, R., JUNGMANN, S., ARNDT, D, SCHUTT, A. & NISSEN, E. (1993). Antineoplastic activity in vitro of free and liposomal alkylphosphocholines. Anti-Cancer Drugs, 4, 57.